Inching Closer to a NASH Cure: Daily Semaglutide Achieves Resolution of NASH but Not Fibrosis after 72 Weeks

Sonali Paul, MD, MS discusses “A Placebo-Controlled Trial of Subcutaneous Semaglutide,” published in NEJM in May 2021. Semaglutide, a GLP-1 receptor agonist for type II diabetes mellitus and weight loss, shows potential as a treatment for NASH in a well-designed, placebo-controlled RCT. May need longer trials to see if it can resolve fibrosis, which is a key treatment goal. Will anxiously await results from ongoing study of weekly high-dose semaglutide in NASH patients.

Om Podcasten

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.